1 Global Fluralaner Market Size (Value) and CAGR (2024-2033)
In 2024, the global Fluralaner market was valued at USD 28.48 million, with a CAGR of 5.73% from 2024 to 2033.
Fluralaner, isoxazoline class compound, is a systemic insecticide and acaricide. Fluralaner is an inhibitor of the arthropod nervous system. Fluralaner inhibits γ-aminobutyric acid (GABA)-gated chloride channels (GABACls) and L-glutamate-gated chloride channels (GluCls). Potency of fluralaner is comparable to fipronil (a phenylpyrazole ectoparasiticide).
Figure Global Fluralaner Market Size (M USD) and CAGR 2024-2033
2 Fluralaner Market Drivers
Increasing Pet Ownership and Humanization of Pets
One of the primary drivers of the Fluralaner market is the growing trend of pet ownership worldwide. According to the American Pet Products Association (APPA), the percentage of households owning pets has increased from 56% in 1988 to 67% in 2020. Dogs and cats remain the most popular pets, with 63.4% and 42.7% of households owning them, respectively. This trend is not limited to the United States; it is a global phenomenon, with many families considering pets as integral members of the household. The humanization of pets has led to increased spending on pet care products, including high-quality veterinary pharmaceuticals like Fluralaner.
The U.S. Food and Drug Administration (FDA) approved Fluralaner under the trade name Bravecto® for flea treatment in dogs in May 2014 and Bravecto® Plus for cats in November 2019. These products have become essential for pet owners seeking to protect their pets from ectoparasites, thereby driving the demand for Fluralaner.
Advantages of Fluralaner
Fluralaner offers several advantages over traditional ectoparasite control methods, which contribute to its growing popularity. As an isoxazoline compound, Fluralaner selectively inhibits arthropod γ-aminobutyric acid (GABA) and L-glutamate-gated chloride channels, making it highly effective against ticks, fleas, and other ectoparasites. Compared to other insecticides, Fluralaner is known for its simple application, easy absorption, safety, high efficiency, and long-lasting effects. Additionally, Fluralaner does not exhibit significant cross-resistance with existing insecticides, making it effective against partially resistant pests. These attributes have positioned Fluralaner as a preferred choice for veterinarians and pet owners, further boosting market demand.
3 Fluralaner Market Restraints
Regulatory Hurdles and Safety Concerns
The production and use of Fluralaner are subject to stringent regulations due to its application in veterinary medicine and potential impact on animal health. Governments worldwide have implemented laws and regulations to ensure the safety and efficacy of veterinary drugs, including Fluralaner. Companies must obtain various approvals and certifications to produce and market Fluralaner, which can be a time-consuming and costly process. Additionally, concerns about the potential side effects of Fluralaner, such as vomiting, pruritus, diarrhea, alopecia, decreased appetite, lethargy, and crusted/ulcerated lesions, have led to increased scrutiny and regulatory oversight. Ensuring the safety and compliance of Fluralaner products is crucial for market acceptance and growth.
Competition from Substitutes
The market for ectoparasite control is highly competitive, with several alternative products available. For instance, Zoetis received FDA approval in January 2022 for Simparica Trio, a combination of sarolaner, moxidectin, and pyrantel chewable tablets for treating tick infections in dogs. The availability of such substitutes poses a significant challenge to the Fluralaner market, as pet owners and veterinarians may opt for alternative products based on cost, efficacy, and safety considerations. Companies must continuously innovate and differentiate their products to maintain a competitive edge in the market.
4 Global Fluralaner Market Size and Share by Type in 2024
In 2024, the Purity ≥ 98% segment is expected to have a market value of 12.87 M USD. This type is defined by its chemical purity, where the active ingredient content is at least 98% but less than 99%. This level of purity is suitable for applications where a high level of efficacy is required, but not necessarily the highest possible purity. Purity ≥ 98% Fluralaner is often used in formulations that balance cost and effectiveness. It is commonly utilized in oral and topical drugs, where the slightly lower purity level still provides effective ectoparasite control while being more cost-effective for certain end uses.
On the other hand, the Purity ≥ 99% segment is projected to have a market value of 15.61 M USD in 2024. This type represents the highest purity level of Fluralaner, with the active ingredient content being at least 99%. The high purity makes it ideal for applications where maximum efficacy and safety are paramount. Purity ≥ 99% Fluralaner is often used in premium veterinary pharmaceuticals, where the highest standards of purity are required to ensure the safety and effectiveness of the product.
Table Global Fluralaner Market Size and Share by Type in 2024
Type | Market Size (M USD) 2024 | Market Share 2024 |
Purity ≥ 98% | 12.87 | 45.18% |
Purity ≥ 99% | 15.61 | 54.82% |
5 Global Fluralaner Market Consumption (KG) and Share by Application in 2024
In 2024, the global consumption of Fluralaner is projected to be 1,618.4 KG. The Oral Drug application is expected to consume 1,127.0 KG, accounting for approximately 69.64% of the total market. Oral Drugs are formulations that can be administered through the mouth and are highly effective in treating ectoparasites in animals. The ease of administration and high efficacy of Fluralaner in oral formulations make it a preferred choice for veterinarians and pet owners. This segment is driven by the increasing demand for convenient and effective treatments for pets, particularly in regions with high pet ownership rates.
The Topical Drug application is expected to consume 491.3 KG in 2024, representing 30.36% of the total market. Topical Drugs are applied directly to the skin and are particularly useful for localized treatments. Fluralaner’s ability to penetrate the skin and provide long-lasting protection against ectoparasites makes it an essential component in topical formulations. This segment is driven by the need for targeted treatments in pets and livestock, especially in regions where ectoparasite infestations are prevalent.
Table Global Fluralaner Market Consumption (KG) and Share by Application in 2024
Application | Market Size (M USD) 2024 | Market Share 2024 |
Oral Drug | 1127.0 | 69.64% |
Topical Drug | 491.3 | 30.36% |
6 Global Fluralaner Market Demand (KG) by Region in 2024
North America is expected to have a demand of 494.6 KG in 2024, driven by the United States, which accounts for the majority of the region’s consumption. The U.S. market is characterized by high pet ownership rates and a strong demand for premium veterinary products. The increasing awareness of pet health and the availability of advanced veterinary care contribute to the high demand for Fluralaner in this region.
Europe is projected to have a demand of 555.3 KG in 2024. The European market is influenced by stringent regulations on veterinary pharmaceuticals and a growing emphasis on animal welfare. Countries such as Germany, the UK, France, Italy, and Spain are significant consumers of Fluralaner, driven by their large pet populations and the need for effective ectoparasite control.
The Asia-Pacific region is expected to have a demand of 374.4 KG in 2024. This region is characterized by rapid economic growth and increasing pet ownership, particularly in countries like China and Japan. The demand for Fluralaner in this region is driven by the growing veterinary market and the need for effective pest control solutions in both pets and livestock. The increasing disposable income and urbanization in countries like India and Southeast Asia also contribute to the growing demand for Fluralaner.
Figure Global Fluralaner Market Demand (KG) by Region in 2024
7 Major Players in Global Fluralaner Market
7.1 Nissan Chemical Corporation
Company Profile: Nissan Chemical Corporation is a leading chemical company headquartered in Japan, with a history dating back to 1887. The company is renowned for its expertise in developing, manufacturing, and selling a wide range of chemical products, including display materials, semiconductors, inorganic materials, herbicides, insecticides, and fungicides. Nissan Chemical has a global sales network, serving customers worldwide.
Business Overview: Nissan Chemical Corporation is at the forefront of chemical innovation, offering custom manufacturing and process research services for pharmaceutical ingredients and intermediates. The company’s commitment to research and development has enabled it to maintain a competitive edge in the global market. Nissan Chemical’s diverse product portfolio and strong technological capabilities make it a key player in the Fluralaner market.
Product Portfolio: Nissan Chemical Corporation’s Fluralaner product is a compound with an isoxazoline skeleton, which is the active ingredient in the veterinary pharmaceutical “Bravecto®.” This product is highly effective in controlling ectoparasites in animals and is marketed globally under the MSD Animal Health brand. The company’s Fluralaner product is known for its high purity and efficacy, making it a preferred choice for veterinarians and pet owners.
Recent Financial Data: In the most recent year, Nissan Chemical Corporation reported a Fluralaner revenue of 20.58 million US dollars, with a gross margin of 45.99%.
7.2 Hikal Ltd.
Company Profile: Hikal Ltd. is a prominent player in the global Fluralaner market, headquartered in India. Established in 1988, the company has built a reputation for providing high-quality active ingredients and intermediates for the life sciences industry. Hikal Ltd. offers a wide range of products and services, catering to the needs of global pharmaceuticals, animal health, biotech, crop protection, and specialty chemicals companies.
Business Overview: Hikal Ltd. specializes in offering comprehensive solutions across the life sciences value chain. The company’s expertise in active ingredients and intermediates has positioned it as a key supplier to major pharmaceutical and animal health companies worldwide. Hikal Ltd.’s commitment to quality and innovation has enabled it to maintain a strong foothold in the competitive Fluralaner market.
Product Portfolio: Hikal Ltd.’s Fluralaner product is designed for anti-tick applications and is known for its high purity and effectiveness. The company’s product portfolio includes various formulations of Fluralaner, catering to different end-use requirements. Hikal Ltd.’s focus on quality and customer satisfaction has made its Fluralaner products highly sought after in the global market.
Recent Financial Data: In the most recent year, Hikal Ltd. reported a Fluralaner revenue of 1.80 million US dollars, with a gross margin of 39.90%.
7.3 Dideu Group
Company Profile: Dideu Group is a leading high-tech enterprise based in China, specializing in the research, development, production, and sales of basic chemicals, fine chemicals, and energy chemicals. Established in 2005, the company has rapidly grown to become a significant player in the global chemical industry. Dideu Group’s focus on innovation and quality has enabled it to establish a strong market presence in the Fluralaner segment.
Business Overview: Dideu Group is committed to providing high-quality chemical products and services to customers worldwide. The company’s expertise in chemical synthesis and production has positioned it as a key supplier to various industries, including veterinary medicine and agriculture. Dideu Group’s dedication to research and development has led to the creation of innovative products that meet the evolving needs of the market.
Product Portfolio: Dideu Group’s Fluralaner product is a high-purity acaricide, designed for effective ectoparasite control. The company’s product portfolio includes various formulations of Fluralaner, catering to different application requirements. Dideu Group’s focus on quality and innovation has made its Fluralaner products highly regarded in the global market.
Recent Financial Data: In the most recent year, Dideu Group reported a Fluralaner revenue of 1.17 million US dollars, with a gross margin of 38.54%.